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salvator@jhmi.eduAbstractObjectives: Adult subjects with untreated, lifetime, isolated GH deficiency (IGHD) due to
a homozygous GHRH receptor gene mutation (MUT/MUT) residing in Itabaianinha, Brazil,
present with lower BMI, higher prevalence of impaired glucose tolerance (IGT), increased
insulin sensitivity (IS), and reduced b-cell function (bCF) when compared with non-
BMI-matched homozygous normal controls. However, the prevalence of diabetes mellitus
(DM) in this cohort is unknown. Comparing their IS and bCF with BMI-matched individuals
heterozygous for the same mutation (MUT/N) may be useful to elucidate the role of the
GH–IGF1 axis in IS and bCF. Thepurposes of thisworkwere to verify theprevalenceof IGTandDM
inadultMUT/MUTsubjects fromthis kindredand to compare IS andbCF inMUT/MUTandMUT/N.
Design: Cross-sectional study.
Methods: We studied most (51) of the living IGHD adults of this kindred who are GH naive. The
oral glucose tolerance test (OGTT) could be performed in 34 subjects, fasting glucose was
measured in 15, while two had a previous diagnosis of DM. The OGTT results of 24 MUT/MUT
subjects were compared with those of 25 BMI-matched MUT/N subjects. IS was assessed by
homeostatic model assessment of insulin resistance (HOMA–IR), quantitative IS check index, and
oral glucose IS index for 2 and 3 h. bCF was assayed by HOMA-b, insulinogenic index, and the
area under the curve of insulin:glucose ratio.
Results: The prevalence of DM and IGT in IGHD was 15.68 and 38.23% respectively.
IS was increased and bCF was reduced in MUT/MUT in comparison with MUT/N.
Conclusions: Lifetime, untreated IGHD increases IS, impairs bCF, and does not provide protection
from diabetes.Key Words
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.0 UEndocrine Connections
(2013) 2, 112–117IntroductionGH regulates b-cell function (bCF) and insulin sensitivity
(IS) both directly and via complex interactions with its
principal mediator, insulin-like growth factor 1 (IGF1) (1).While GH reduces IS, IGF1 increases it. The hyper-
glycemic action of GH occurs mainly in the liver, and
the hypoglycemic action of IGF1 occurs mainly insed under a Creative Commons
nported License.
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2–6 2 :113muscle (2). At least in animal models, IGF1 also has an
important role in the development of b-cell mass (3, 4, 5).
Genetic forms of GH resistance or GH deficiency (GHD)
may be useful to clarify the role of the GH–IGF1 axis in
regulating insulin secretion and action in humans.
In contrast to obese individuals, who present with
reduced IS, GH-resistant (Laron syndrome) dwarfs present
with normal IS – as measured by homeostatic model
assessment of insulin resistance (HOMA–IR) – despite
increased fat mass percentage (6). In these subjects, bCF –
assessed by the insulin response during an oral glucose
tolerance test (OGTT) – also seems to be impaired,
especially in subjects older than 23 years, with a case of
diabetes mellitus (DM) diagnosed in a 38-year-old patient
due to bCF exhaustion (7). However, recently, in a large
Ecuadorian study of kindred with Laron syndrome, none
of the GH-resistant individuals self-reported to have DM
(8). This has attracted the attention of scientific and lay
media, as has been interpreted as showing that in the
absence of GH action, DM does not occur.
We have previously described a large extended
kindred with congenital isolated GHD (IGHD) due to
the c.57C1GOA mutation in the GHRH receptor
(GHRHR) gene (GHRHR), who reside in Itabaianinha
county in northeast Brazil (9). Individuals homozygous
for this mutation (MUT/MUT) have very low serum GH
and IGF1 levels (10), resulting in severe proportionate
dwarfism. Despite several cardiovascular risk factors (11),
they exhibit normal longevity (12) and no evidence of
premature atherosclerosis (13). We have recently studied
24 IGHD subjects and found that, despite an increase in
percentage fat mass they do not have insulin resistance,
but have impaired bCF and a higher prevalence of
impaired glucose tolerance (IGT) when compared with
homozygous (N/N) normal controls (14). One important
limitation of our previous report was that the MUT/MUT
and N/N groups were not matched for BMI. It is difficult
to match MUT/MUT with N/N individuals, as reduced
BMI is a hallmark of congenital GHD. However, subjects
who are heterozygous for the mutation (MUT/N) have a
partial phenotype. Despite normal stature and serum
IGF1 levels, they have reduced lean body mass and a
similar BMI compared with MUT/MUT subjects (15).
This renders the MUT/N group an ideal one to compare
with the MUT/MUT group.
The purposes of this work were i) to extend the study
of prevalence of impaired fasting glucose (IFG) and DM
to all the adult IGHD subjects from Itabaianinha and
ii) to compare the prevalence of IGT and the degree of
IS and bCF in MUT/MUT and MUT/N subjects.http://www.endocrineconnections.org
DOI: 10.1530/EC-13-0014
 2013 The authors
Published by Bioscientifica LtdMaterials and methods
Design
This was a cross-sectional study performed in Itabaianinha
county in the northeastern Brazilian state of Sergipe.
Subjects were recruited by an advertisement, placed in the
local dwarfs’ association building, and by word of mouth.
Two groups were enrolled: MUT/MUT (IGHDhomozygous
individuals for the GHRHR c.57C1GOA mutation) and
MUT/N (heterozygous for the same mutation living in the
same community). Both the Federal University of Sergipe
and the Johns Hopkins University Institutional Boards
approved this study. All subjects signed a written informed
consent. A two-step protocol was performed: the first
epidemiological and the second physiological.
Experiment 1 " We have identified 52 living untreated
adult MUT/MUT individuals, 26 females, age 45.08 (20.03)
years, range 18–97 years. Two of them had a previous
diagnosis of DM (one on metformin and the other
on metformin and glimepiride) and did not undergo
OGTT. Depending on logistics and subjects’ availability,
some had only fasting glucose, some partial, and some
complete OGTT. One individual declined to participate.
We measured fasting glucose in 15 individuals, performed
OGTT with glucose measurements at 0 and 120 min in
10 individuals, and complete OGTT (with glucose and
insulin measurements at 0, 30, 60, 90, 120, and 180 min)
in 24 additional individuals, for a total of 51 subjects.
Data of this experiment are descriptive andwere compared
with Brazilian epidemiological studies.
Experiment 2 " The results of previously reportedOGTT
performed in 24 MUT/MUT subjects (14) were compared
with those of 25 age- and sex-matched MUT/N individ-
uals. Glucose and insulin were measured at 0, 30, 60, 90,
120, and 180 min. Exclusion criteria were as follows: age
!25 or more than 60 years, known history of DM,
excessive alcohol use, chronic and systemic diseases,
previous GH use, use of drugs that could impact IS and
bCF, and fasting glucose R126 mg/dl.Laboratory methods and calculations
Glucosewasmeasured by the enzymatic Trinder colorimetric
test on the day of each test. Sera for insulin were frozen at
K40 8C and assayed together. Insulin was measured by an
immunofluorometric assay having a sensitivity of 0.5 mU/ml
(PerkinElmer Life and Analytical Sciences, Turku, Finland),
and intra-assay and interassay variabilities were 2.5 andThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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HOMA–IR, measured by the formula: fasting serum insulin
(mU/ml)!fasting plasma glucose (mmol/l)/22; ii) quan-
titative IS check index (QUICK), measured by the formula:
1/(log insulin (mU/ml)Clog glucose (mg/dl)); and iii) oral
glucose IS index for 2 h (OGIS2) and 3 h (OGIS3). bCF
was estimated using the basal glucose and insulin values
by HOMA-b (20!fasting insulin)/(fasting glucose
(mmol/l)K3.5); the first rapid phase of insulin secretion,
using the insulinogenic index (IGI) (insulin time 30Kinsulin
time 0 (mU/ml))/(glucose time 30Kglucose time 0 (mg/dl));
and the total glucose-adjusted insulin response during the
OGTT, by the area under the curve of insulin:glucose ratio
(AUC I (mU/ml):G (mg/dl)) (14).Anthropometric measurements
Height, body weight, waist circumference (W) at half
the distance between the last rib and the superior margin
of iliac crest, and hip circumference (H) at the level of
femoral trochanters were measured. The W:H ratio was
calculated, and BMI was obtained by the formula: weight
(kg)/height (m2).Table 1 Anthropometric and metabolic data in 24 MUT/MUT
subjects and 25 MUT/N subjects involved in experiment 2. Data
are expressed as mean (S.D.), except for HOMA–IR, HOMA-b, and
IGI, which are expressed as median (interquartile range).
MUT/MUT MUT/N PPrediabetes and diabetes diagnosis
Current American Diabetes Association criteria were
followed. Prediabetes was defined by the presence of
either IFG (fasting glucose levels between 100 and
125 mg/dl) and/or IGT (2-h glucose level during OGTT
between 140 and 199 mg/dl). DM was defined by a fasting
glucose level R126 mg/dl or a 2-h glucose level during
OGTTR200 mg/dl.
Age (years) 39.25 (11.73) 40.08 (10.87) 0.798
Sex (males/females) 12/12 12/13 1.000
Height (cm) 128.21 (9.42) 160.66 (9.27) !0.001
Weight (kg) 37.2 (5.95) 59.35 (10.26) !0.001
BMI (kg/m2) 22.9 (4.68) 22.88 (2.79) 0.983
Waist (cm) 76.5 (9.99) 80.46 (7.72) 0.139
Hip (cm) 81.94 (8.01) 91.95 (7.9) !0.001
W:H ratio 0.93 (0.09) 0.88 (0.09) 0.033
HOMA–IR 0.55 (0.49) 0.96 (0.57) 0.004
QUICKI 0.43 (0.04) 0.39 (0.04) 0.005Statistical analysis
Variables with normal and not-normal distribution were
compared by t-test andMann–Whitney U test respectively.
Data of normal distribution are reported as mean (S.D.).
Data with not-normal distribution (HOMA–IR, HOMA-b,
IGI, QUICK-I, and BMI) are reported as median (inter-
quartile range). Statistical analysis was performed using
the Software SPSS/PC 15.0 (SPSS, Inc.). P values %0.05
were considered statistically significant.OGIS2 444.3 (49.6) 413.18 (59.74) 0.054
OGIS3 453.6 (62.14) 430.14 (72.2) 0.230
HOMA-b 28.1 (14.52) 52.24 (42.4) 0.005
IGI 0.4 (0.36) 0.99 (0.98) 0.001
AUC I (mU/ml):G
(mg/dl)
0.22 (0.08) 0.36 (0.17) 0.001Results
Experiment 1
The prevalence of IFG was 9.8% (five cases). The
prevalence of DM was 15.7% (eight cases: two cases werehttp://www.endocrineconnections.org
DOI: 10.1530/EC-13-0014
 2013 The authors
Published by Bioscientifica Ltdpreviously diagnosed, two were diagnosed by fasting
glucose R126 mg/dl, and four by 2-h post-glucose value
R200 mg/dl). The prevalence of IGT in the MUT/MUT
subject who underwent OGTT was 13/34 (38.2%).
However, four of these subjects had IFG. Therefore, the
prevalence of IGT in subjects with normal fasting glucose
is 9/34 (26.4%).Experiment 2
As expected, height and weight were lower in MUT/MUT
subjects than in MUT/N subjects. BMI was similar, while
W:H ratio was higher in MUT/MUT subjects. HOMA–IR
was lower and QUICKI was higher in MUT/MUT subjects
than in MUT/N subjects (PZ0.004 and PZ0.005 respect-
ively). OGIS2 had a trend toward being higher in
MUT/MUT subjects than in MUT/N subjects (PZ0.054),
while OGIS3 was similar (Table 1). HOMA-b, IGI, and AUC
I:G were lower in MUT/MUT subjects than in MUT/N
subjects (PZ0.005, PZ0.001, and PZ0.002 respectively;
Table 1 and Fig. 1).This work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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Figure 1
Boxplot of (A) HOMA-b, (B) IGI, and (C) AUC I (mU/ml):G (mg/dl) in 24
MUT/MUT subjects and 25 MUT/N subjects. The horizontal line in the
middle of the rectangle is the median, the low margin of the rectangle
is the 25th percentile, and the high margin of the rectangle is the
75th percentile.
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Recently, there has been great interest – both in the
medical literature and in the lay press – about the report
that adult dwarf individuals with GH resistance from a
large Ecuadorian kindred do not have diabetes or
cancer (8). Conversely, the prevalence of DM and IGT in
our IGHD cohort was 15.7 and 38.2% respectively.
Although the prevalence of DM we have observed was
similar to that of DM in two population studies in Brazil
(12.1 and 13.5%), the prevalence of IGT is even higher
than that reported in these studies (5 and 7.7% respec-
tively) (16, 17). The DM prevalence in our cohort may
have been even higher if we had been able to perform
an OGTT in all the 51 subjects. These findings prove
that lifetime IGHD due to a GHRHR mutation – contrary
to what has been reported in a large GH-resistant cohort
– does not protect against development of DM.
It is possible that the metabolic consequences of GH
resistance and GHD are different, particularly because
patients with GHRHR mutations secrete a small but
detectable amount of GH (18), which may contribute to a
lower IS than the Laronmodel (where theGHeffect is likely
to be completely absent). It is conceivable that the lack of a
GHRH effect per se may have additional consequences on
glucosemetabolism independent ofGHD. It is also possible
that the self-reporting approachmay have underestimated
the real prevalence of DM in the Ecuadorian subjects.
Indeed, diabetes and its complications have been described
in patients with Laron dwarfism (19, 20, 21). Accordingly,
if we had relied only on self-reporting, we would have
concluded that only two subjects (3.92%) have diabetes.
Interestingly, despite reduced glucose tolerance, our
IGHD individuals present increased IS in comparison
with a BMI-matched MUT/N group. These data are similar
to the previous finding of increased IS in MUT/MUT in
comparison to N/N. The limitation of the previous paper
was that theMUT/MUT andN/N groups were not perfectly
matched for BMI (14). Reduced BMI is a hallmark of
congenital GHD (22) and GH resistance (6), due to small
muscles and bones, and it is very difficult to match
MUT/MUT with N/N individuals by BMI. In this study, we
were fortunate to have a MUT/N group with a BMI similar
to that of MUT/MUT group. Therefore, the present data
confirm our previous conclusion that IGHD per se, despite
increase in percentage fat mass, and contrary to what has
been reported in adult-onset GHD (AOGHD), does
not cause insulin resistance. We hypothesize that the
difference in IS (increased in our IGHD individuals and
reduced in AOGHD individuals) is probably caused byThis work is licensed under a Creative Commons
Attribution 3.0 Unported License.
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5–6 2 :116different degrees of GHD, and possibly influenced by
co-morbidities, such as a lack of other pituitary hormones
and associated therapies in AOGHD (23), and is not due to
methodological issues. Indeed, the OGTT with simul-
taneous glucose and insulinmeasurement has an excellent
correlation with the euglycemic–hyperinsulinemic clamp
(24), the ‘gold standard’ method to assess IS, used in
acquired AOGHD (25).
The increase of IS in the IGHD groupmay be caused by
the marked reduction in GH levels and thereby lack of
insulin antagonism. Additionally, increased muscle IS
may be due to an increase in the molar ratio of total IGF
to IGF binding protein type 3 (10), similar to what seen in
healthy centenarians (26).
Such an increase in IS does not result in the prevention
of diabetes. We speculate that this is due to the important
effect of the GH–IGF1 axis on bCF, whose measures were
reduced in MUT/MUT subjects. This reduction in bCFmay
be the decisive factor for the high prevalence of IGT in
IGHD subjects. Conversely, as MUT/N subjects have
normal IGF1 levels, they may have normal bCF.
Similar to our IGHD subjects, little mice (also carrying
a homozygous GHRHR mutation like our subjects) (27)
and mice with GH receptor gene ablation (GHRKO) (3) are
hypersensitive to insulin, but have IGT due to a reduced
number of pancreatic b cells and reduced insulin
secretion, probably due to reduced pancreatic b-cell
mass. Accordingly, Igf1 gene overexpression in GHRKO
animals restores b-cell mass, normalizing insulin pro-
duction, and glucose tolerance (4).
In conclusion, severe congenital lifetime IGHD
increases IS but impairs bCF and does not provide
protection from DM, whose prevalence is similar to that
of the general Brazilian population. Therefore, the dream
of a ‘diabetes-free life’ is not present even in severe
congenital IGHD.Declaration of interest
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